{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:29:26Z","timestamp":1787311766286,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40256-026-00812-w","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:28:39Z","timestamp":1783686519000},"page":"589-602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies"],"prefix":"10.1007","volume":"26","author":[{"given":"Christopher Daniel","family":"Tristan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irnizarifka","family":"Irnizarifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlangga Masykur","family":"Kynaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellisa","family":"Gani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Aldo","family":"Wijayanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An Aldia","family":"Asrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Pranata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"36","key":"812_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"1","key":"812_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-025-00728-8","volume":"13","author":"J Ran","year":"2025","unstructured":"Ran J, Zhou P, Wang J, Zhao X, Huang Y, Zhou Q, et al. Global, regional, and national burden of heart failure and its underlying causes, 1990\u20132021: results from the global burden of disease study 2021. Biomark Res. 2025;13(1):16.","journal-title":"Biomark Res."},{"issue":"1","key":"812_CR3","doi-asserted-by":"publisher","first-page":"0","DOI":"10.56499\/jppres_14.1.2253","volume":"14","author":"CD Tristan","year":"2026","unstructured":"Tristan CD, Myrtha R, Wiyono N, Irnizarifka I. Current landscape and future potential of sodium-glucose cotransporter 2 inhibitors in heart failure\u202f: A systematic review and bibliometric analysis. J Pharm Pharmacogn Res. 2026;14(1):0\u20132.","journal-title":"J Pharm Pharmacogn Res."},{"issue":"12","key":"812_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"21","key":"812_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"16","key":"812_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"8","key":"812_CR7","doi-asserted-by":"publisher","first-page":"EVIDoa2500173","DOI":"10.1056\/EVIDoa2500173","volume":"4","author":"VN Shah","year":"2025","unstructured":"Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, et al. Semaglutide in adults with type 1 diabetes and obesity. NEJM Evid. 2025;4(8):EVIDoa2500173.","journal-title":"NEJM Evid."},{"issue":"11","key":"812_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"PH Wj","year":"2021","unstructured":"Wj PH, Br L, Salvatore C, Melanie D, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"10456","key":"812_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet (London, England). 2024;404(10456):949\u201361.","journal-title":"Lancet (London, England)."},{"issue":"12","key":"812_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"key":"812_CR11","doi-asserted-by":"crossref","unstructured":"Diallo A, Carlos-Bolumbu M, Duc P, Galtier F. Prevention of cardiovascular events in heart failure with mildly reduced or preserved ejection fraction: a comprehensive network meta-analysis of eight randomized controlled trials using reconstructed individual patient\u2019s data. eClinicalMedicine [Internet]. 2025;88:103506. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589537025004390","DOI":"10.1016\/j.eclinm.2025.103506"},{"issue":"1","key":"812_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13098-025-01635-6","volume":"17","author":"A Mousavi","year":"2025","unstructured":"Mousavi A, Shojaei S, Soleimani H, Semirani-Nezhad D, Ebrahimi P, Zafari A, et al. Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025;17(1):68.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"812_CR13","doi-asserted-by":"publisher","first-page":"19351","DOI":"10.1038\/s41598-019-55524-w","volume":"9","author":"M Castellana","year":"2019","unstructured":"Castellana M, Cignarelli A, Brescia F, Perrini S, Natalicchio A, Laviola L, et al. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. Sci Rep. 2019;9(1):19351.","journal-title":"Sci Rep"},{"key":"812_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108737","volume":"174","author":"T Karagiannis","year":"2021","unstructured":"Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;174:108737.","journal-title":"Diabetes Res Clin Pract"},{"issue":"22","key":"812_CR15","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Fletcher RA, Heath L, Perkovic A, Vaduganathan M, Badve SV, et al. Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation. 2024;150(22):1781\u201390.","journal-title":"Circulation"},{"key":"812_CR16","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. statement: An updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.","journal-title":"BMJ"},{"issue":"Suppl_3","key":"812_CR17","doi-asserted-by":"publisher","first-page":"A4363938","DOI":"10.1161\/circ.152.suppl_3.4363938","volume":"152","author":"S Mensah","year":"2025","unstructured":"Mensah S, Kwaah P, Kwakye AO, Sudarshan B, Patel B. Combination glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapy reduces admissions and death in patients with heart failure with reduced ejection fraction. Circulation. 2025;152(Suppl_3):A4363938\u2013A4363938. https:\/\/doi.org\/10.1161\/circ.152.suppl_3.4363938.","journal-title":"Circulation"},{"key":"812_CR18","doi-asserted-by":"crossref","unstructured":"Kalaydzhiev P, Velikova T, Voynova G, Ilieva R, Spasova N, Yakov S, et al. Cardiometabolic improvements, sleep apnea reduction, and biomarker modulation under dual GLP-1RA and SGLT2i therapy: a prospective study. PHARMACIA [Internet]. 2025;72:1\u201311. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0428029625001684","DOI":"10.3897\/pharmacia.72.e166690"},{"key":"812_CR19","doi-asserted-by":"crossref","unstructured":"Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, et al. Combination therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in heart failure patients with type 2 diabetes. BMJ open diabetes Res care. 2025 Nov;13(6).","DOI":"10.1136\/bmjdrc-2025-005364"},{"issue":"11","key":"812_CR20","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","volume":"12","author":"R Patel","year":"2024","unstructured":"Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, et al. GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors. JACC Heart Fail. 2024;12(11):1814\u201326.","journal-title":"JACC Heart Fail."},{"key":"812_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.amjcard.2022.07.012","volume":"181","author":"PD Lopez","year":"2022","unstructured":"Lopez PD, Bhatia K, Bohra C. Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure. Am J Cardiol. 2022;181:87\u201393. https:\/\/doi.org\/10.1016\/j.amjcard.2022.07.012.","journal-title":"Am J Cardiol"},{"key":"812_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112452","volume":"228","author":"C Sardu","year":"2025","unstructured":"Sardu C, Vittoria L, Rinaldi L, Carlo F, Cozzolino D, Nappo F, et al. Diabetes Research and Clinical Practice Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications\u202f: A multicenter observational study. Diabetes Res Clin Pract. 2025;228:112452. https:\/\/doi.org\/10.1016\/j.diabres.2025.112452.","journal-title":"Diabetes Res Clin Pract"},{"key":"812_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaf014","author":"SY Chen","year":"2025","unstructured":"Chen SY, Wu JY, Liao KM, Lin YM. Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cot ra nsporter 2 inhibitors in patients with at herosc lerotic c a rdiovascula r disease and hea rt fa ilure\u202f: a cohort study. Eur Hear J Cardiovasc Pharmacother. 2025. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf014.","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"issue":"7\u20138","key":"812_CR24","first-page":"814","volume":"83","author":"A Zhang","year":"2025","unstructured":"Zhang A, Yu J, Ke J, Yin P, Zhang J, Wang C, et al. SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in diabetic cardiomyopathy: A prospective cohort study. Kardiol Pol. 2025;83(7\u20138):814\u201322.","journal-title":"Kardiol Pol"},{"issue":"4","key":"812_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"6","key":"812_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci."},{"issue":"11","key":"812_CR27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ajh\/hpae092","volume":"37","author":"V Vallon","year":"2024","unstructured":"Vallon V. State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024;37(11):841\u201352.","journal-title":"Am J Hypertens"},{"key":"812_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.873108","author":"X Chen","year":"2022","unstructured":"Chen X, Yang Q, Bai W, Yao W, Liu L, Xing Y, et al. Dapagliflozin attenuates myocardial fibrosis by inhibiting the TGF-\u03b21\/Smad signaling pathway in a normoglycemic rabbit model of chronic heart failure. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.873108.","journal-title":"Front Pharmacol"},{"key":"812_CR29","doi-asserted-by":"crossref","unstructured":"Dyck JRB, Sossalla S, Hamdani N, Coronel R, Weber NC, Light PE, et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. J Mol Cell Cardiol [Internet]. 2022;167:17\u201331. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0022282822000499","DOI":"10.1016\/j.yjmcc.2022.03.005"},{"key":"812_CR30","doi-asserted-by":"crossref","unstructured":"Stankovic S, Miloradovic Z, Petrovic V, Stoiljkovic M. Redefining SGLT2 inhibitors through cytoprotective mechanisms. Eur J Pharmacol [Internet]. 2026;1016:178647. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0014299926001299","DOI":"10.1016\/j.ejphar.2026.178647"},{"issue":"1","key":"812_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12933-025-02777-7","volume":"24","author":"TT Yoo","year":"2025","unstructured":"Yoo TT, Baek IH, Stoletniy L, Hilliard A, Sakr A, Doycheva D. Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. Cardiovasc Diabetol. 2025;24(1):227.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"812_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12997\/jla.2022.11.1.1","volume":"11","author":"H Saucedo-Orozco","year":"2022","unstructured":"Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD. SGLT2 inhibitors and ketone metabolism in heart failure. J lipid Atheroscler. 2022;11(1):1\u201319.","journal-title":"J lipid Atheroscler."},{"issue":"1","key":"812_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z.","journal-title":"Signal Transduct Target Ther"},{"key":"812_CR34","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.3390\/jcm14196758","volume":"14","author":"HM Yang","year":"2025","unstructured":"Yang HM. GLP-1 agonists in cardiovascular diseases: mechanisms, clinical evidence, and emerging therapies. J Clin Med. 2025;14:6758.","journal-title":"J Clin Med"},{"issue":"1","key":"812_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40885-024-00279-4","volume":"30","author":"HY Lee","year":"2024","unstructured":"Lee HY, Ko SH, Park S, Kim K, Kim SY, Cho IJ, et al. The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension. Clin Hypertens. 2024;30(1):24.","journal-title":"Clin Hypertens"},{"issue":"4","key":"812_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40256-022-00527-8","volume":"22","author":"T Koufakis","year":"2022","unstructured":"Koufakis T, Liberopoulos EN, Kotsa K. A horse, a jockey, and a therapeutic dilemma: choosing the best option for a patient with diabetes and coronary artery disease. Am J Cardiovasc Drugs. 2022;22(4):357\u201361. https:\/\/doi.org\/10.1007\/s40256-022-00527-8.","journal-title":"Am J Cardiovasc Drugs"},{"key":"812_CR37","first-page":"2595","volume":"13","author":"N Homor\u00f3di","year":"2025","unstructured":"Homor\u00f3di N, Varga \u00c9, Szab\u00f3 Z, Sztanek F, Harangi M. Complementary yet distinct roles of GLP-1 receptor agonists and SGLT2 inhibitors in cardiovascular risk reduction. Biomed. 2025;13:2595.","journal-title":"Biomed"},{"issue":"1","key":"812_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, H\u00e4nselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69\u201377.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"812_CR39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500\u20138. https:\/\/doi.org\/10.1001\/jama.2016.10260.","journal-title":"JAMA"},{"issue":"5","key":"812_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"key":"812_CR41","doi-asserted-by":"crossref","unstructured":"Dakota I, Wijayanto MA, Salsabilla A, Nugrahani D, Sunjaya AF, Rachmayanti S, et al. Diagnostic and prognostic implications of growth differentiation factor 15 in heart failure with preserved ejection fraction\u202f: a systematic review and meta-analysis. 2025;1\u201317.","DOI":"10.7717\/peerj.20168"},{"key":"812_CR42","doi-asserted-by":"crossref","unstructured":"Tristan CD, Wijayanto MA, Kynaya EM, Budiono EA, Huang W, Myrtha R, et al. Prevalence and factors associated with pulmonary hypertension in heart failure with preserved ejection fraction: a meta-analysis and meta-regression. Cardiol Rev [Internet]. 2026; Available from: https:\/\/journals.lww.com\/cardiologyinreview\/fulltext\/9900\/prevalence_and_factors_associated_with_pulmonary.804.aspx","DOI":"10.1097\/CRD.0000000000001235"},{"issue":"7","key":"812_CR43","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","volume":"85","author":"M Kc","year":"2025","unstructured":"Kc M, Bb A, Zm R, Dustin R, et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure. JACC. 2025;85(7):699\u2013706. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.001.","journal-title":"JACC"},{"issue":"4","key":"812_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1001\/jamacardio.2026.0083","volume":"11","author":"X Chen","year":"2026","unstructured":"Chen X, Liu X, Li R, Wang Z, Liang Y, Zhang L, et al. Long-term outcomes of left bundle-branch pacing vs biventricular pacing in heart failure: the HeartSync-LBBP randomized clinical trial. JAMA Cardiol. 2026;11(4):352\u20139.","journal-title":"JAMA Cardiol."},{"issue":"3","key":"812_CR45","doi-asserted-by":"publisher","first-page":"A4370885","DOI":"10.1161\/circ.152.suppl_3.4370885","volume":"152","author":"A Murshid","year":"2025","unstructured":"Murshid A, Awad M, Ahmad S, Alawad S, Thyagaturu H. Abstract 4370885: outcomes of tirzepatide vs semaglutide in patients with type 2 diabetes and heart failure with preserved ejection fraction: a retrospective cohort analysis. Circulation [Internet]. 2025;152(3):A4370885\u2013A4370885. https:\/\/doi.org\/10.1161\/circ.152.suppl_3.4370885.","journal-title":"Circulation [Internet]."},{"key":"812_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2025.103372","author":"AW Khan","year":"2025","unstructured":"Khan AW, Ahmad M, Aman A, Ishaq M, Ali Z, Asif T. E-111 comparing the effects of tirzepatide vs semaglutide on long-term outcomes in heart failure patients with co-existing chronic kidney disease: A US cohort propensity-matched study. J Soc Cardiovasc Angiogr Interv. 2025. https:\/\/doi.org\/10.1016\/j.jscai.2025.103372.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"812_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111806","author":"LD Lomeli","year":"2024","unstructured":"Lomeli LD, Kodali AM, Tsushima Y, Mehta AE, Pantalone KM. The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis. Diabetes Res Clin Pract. 2024. https:\/\/doi.org\/10.1016\/j.diabres.2024.111806.","journal-title":"Diabetes Res Clin Pract"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00812-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00812-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00812-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:45:51Z","timestamp":1787309151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00812-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00812-w","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No external funding was used in the preparation of this manuscript.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christopher Daniel Tristan, Irnizarifka Irnizarifka, Erlangga Masykur Kynaya, Mellisa Gani, Matthew Aldo Wijayanto, An Aldia Asrial, and Raymond Pranata declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christopher Daniel Tristan - Conceptualization, methodology, data curation, formal analysis, writing \u2013 original draft; Irnizarifka Irnizarifka - Conceptualization, methodology, data curation, formal analysis, writing \u2013 original draft; Erlangga Masykur Kynaya - methodology, data curation, formal analysis; Mellisa Gani - writing \u2013 original draft, visualisation; Matthew Aldo Wijayanto - formal analysis, writing \u2013 original draft; An Aldia Asrial \u2013 critical manuscript revision; Raymond Pranata \u2013 supervision, critical manuscript revision. All authors read and approved the final version of this manuscript.","order":3,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":8,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No artificial intelligence (AI) tools were used in data collection, statistical analysis, or interpretation of the results. However, during the manuscript revision process, Grammarly, as a large-language model, was used solely for assisting with English grammar, spelling, and language clarity.","order":9,"name":"Ethics","label":"Declaration of Artificial Intelligence Use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}